Dysosmobacter welbionis as Next Generation Probiotics
Therapeutic candidates such as Akkermansia, Lactobacillus, Bifidobacterium, and Dysosmobacter welbionis (D. welbionis) have D. welbionis. Creative Biolabs offers well-established and innovative One-Stop-Shop live biotherapeutic products (LBP) solutions. We are flexible to meet the unique needs of LBP client projects about D. welbionis.
Introduction of D. welbionis
Fig.1 Scanning electron micrographs of cells of strain J115T in late exponential phase. (Le, 2020)
D. welbionis is a novel species of Ruminococcaceae. The cells are obligatory anaerobic, non-pigmented, non-spore forming, non-motile, and Gram-stain-negative. Cells form straight rods mainly 1.8-3.0μm but often form elongated rods whatever the growing phase. Colonies on solid modified YCFA after 72h of incubation at 37℃ under anaerobic conditions are punctiform, cream, translucent, circular, entire, slightly convex, and smooth. The type strain, J115T (=DSM 106889T=LMG 30601T) was isolated from a faecal sample from a healthy 25-year-old female in July 2017. It presents in 70% of the general population at a relatively high abundance (0-9%). Strain J115T produced acid from myo-inositol but not from Dglucose, D-ribose or D-xylose. Butyric acid was the major end-product of myo-inositol. The genomic DNA G+C content was 58.92 mol%. Strain J115T was also related to the not-yet-cultured bacterium Oscillospira guilliermondii (92-93%similarity). It is important to note that this bacterium has been grown in a well-defined medium suitable for use of the bacterium in humans. This makes it possible to bypass the difficulties previously faced in investigating A. muciniphila.
Recently, D. welbionis was also thought to have beneficial effects similar to those of A. muciniphila. Supplementation with live D. welbionis J115T (1.0×109 CFU daily) in mice, but not with the same pasteurized strain, induced a decrease in fat mass gain, insulin resistance, and white adipose tissue hypertrophy and inflammation. These results suggest that D. welbionis J115T directly and beneficially influences host metabolism and is a strong candidate for the development of next-generation beneficial bacteria targeting obesity and associated metabolic diseases.
Fig.2 Live D. welbionis J115T prevents diet-induced obesity in mice. (Le, 2022)
What Services Can We Provide for D. welbionis at Creative Biolabs?
D. welbionis Related Products at Creative Biolabs
We supply a variety of D. welbionis strains of different preservation numbers as below. If you need other strains, please contact us.
-
Customized strain culture supernatant. (e.g.: for animal research)
-
Customized strain lyophilized powder containing certain CFU. (e.g.: for animal research)
Creative Biolabs will work with you as part of your team to not only provide comprehensive quality data but also timely and effective solutions to any challenges that you face in the development of D. welbionis. Please feel free to contact us. We are happy to discuss more details about D. welbionis with you.
References
-
Le, R.T.; et al. Dysosmobacter welbionis gen. nov., sp. nov., isolated from human faeces and emended description of the genus Oscillibacter. International journal of systematic and evolutionary microbiology. 2020, 70(9): 4851-4858.
-
Le, R.T et al. Dysosmobacter welbionis is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice. Gut. 2022, 71(3): 534-543.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
